Acute Myeloid Leukemia-associated pneumonia mortality trends (1999–2023) and ARIMA-based projections through 2050 in geriatric u.S. adults

H Haseeb Tareen (1Henry Ford Hospital, Jackson, United States) A Allah Dad (2Shiekh Zayed Medical College, Rahim Yar Khan, Pakistan) M Muhammad Arham (Sheikh Zayed Medical College, Multan, Pakistan) S Saif Ali Khan (4Northwest Medical Center, Tucson, United States) A Ali Zubair (Sheikh Zayed Medical College, Rahim Yar Khan, Pakistan) M Muhammad Saad Khan (4Jinnah Sindh Medical University, Karachi, Pakistan) M Muhammad Taha Altaf (Ameer-ud-Din Medical College, Lahore, Lahore, Pakistan) S Shahzaib Maqbool (6HCA Healthcare Kansas City/Centerpoint Medical, Kansas City, United States) K Kinza Bakht (2Shiekh Zayed Medical College, Rahim Yar Khan, Pakistan) F Fahad Saleem H Hafsa Ahmed (1Emory University of Winship Cancer Institute, Heamtolgy and Oncology, ATLANTA, United States) S Safi Ur Rehman Daim (6Carle Foundation Hospital, Urbana, United States) M Manya Kumar (5Danbury Hospital, Danbury, United States) V Venumadhavi Gogineni (11Henry Ford Health, Detroit, United States)

Abstract

Abstract Introduction: Pneumonia is a prevalent and serious complication in acute myeloid leukemia (AML), affecting more than 25% of treated patients and substantially contributing to adverse clinical outcomes. The hypothesis posits that AML-associated pneumonia mortality demonstrates significant socioeconomic and regional disparities across the U.S. population. Objective: To examine mortality trends in AML-associated pneumonia among U.S. adults aged ≥65 from 1999 to 2023 and project rates through 2050, focusing on socioeconomic disparities. Methods: Mortality data from the CDC WONDER “Multiple Cause of Mortality” dataset (1999–2023) were analyzed using ICD-10 codes for pneumonia (18) and AML (C92). Age-adjusted mortality rates (AAMR) per million were standardized to the 2000 U.S. population. Joinpoint regression estimated annual percent change (APC) with 95% CI, using a significance threshold of p < 0.05. Trends were forecasted using ARIMA after ADF-based stationarity testing. Results: A total of 12,447 AML-associated pneumonia deaths were recorded. AAMR rose to 13.7 per million (95% CI: 12.7–14.7) in 2020. The ARIMA model, with AIC 33.41 and RMSE 1.05, projected AAMR of 11.6 in 2030 (CI: 8.73–14.47), 2040 (CI: 7.13–16.07), and 2050 (CI: 5.97–17.23). Males consistently exhibited higher AAMR, reaching 16.15 in 2050 (CI: 14.87–17.43), compared to females at 7.9 (CI: -0.69–16.49). Historically, males exhibited higher AAMR (peak: 19.9, 95% CI: 18.1–21.7) than females (9.6, 95% CI: 8.5–10.7). A significant increase was noted among non-Hispanic Whites (APC: 0.57%, 95% CI: 0.27–0.91; p < 0.001). The Western region reported the highest AAMR, maintaining 12.9 per million from 1999 to 2023. Large Central Metro areas peaked at 14.9 per million (95% CI: 12.9–17.0) in 2020. California had the highest state-level AAMR (14.5, 95% CI: 13.7–15.2).Conclusion: Mortality from AML-associated pneumonia increased from 1999 to 2023, peaking post-COVID. Significant disparities were observed among males, non-Hispanic Whites, residents of the West, large metropolitan areas, and California, indicating the necessity for targeted interventions in response to projected rising trends.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 6932-6932
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (14)

H

Haseeb Tareen

1Henry Ford Hospital, Jackson, United States

A

Allah Dad

2Shiekh Zayed Medical College, Rahim Yar Khan, Pakistan

M

Muhammad Arham

Sheikh Zayed Medical College, Multan, Pakistan

S

Saif Ali Khan

4Northwest Medical Center, Tucson, United States

A

Ali Zubair

Sheikh Zayed Medical College, Rahim Yar Khan, Pakistan

M

Muhammad Saad Khan

4Jinnah Sindh Medical University, Karachi, Pakistan

M

Muhammad Taha Altaf

Ameer-ud-Din Medical College, Lahore, Lahore, Pakistan

S

Shahzaib Maqbool

6HCA Healthcare Kansas City/Centerpoint Medical, Kansas City, United States

K

Kinza Bakht

2Shiekh Zayed Medical College, Rahim Yar Khan, Pakistan

F

Fahad Saleem

H

Hafsa Ahmed

1Emory University of Winship Cancer Institute, Heamtolgy and Oncology, ATLANTA, United States

S

Safi Ur Rehman Daim

6Carle Foundation Hospital, Urbana, United States

M

Manya Kumar

5Danbury Hospital, Danbury, United States

V

Venumadhavi Gogineni

11Henry Ford Health, Detroit, United States